Mar 12
|
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
|
Mar 4
|
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
|
Feb 23
|
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results
|
Jan 15
|
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
|
Dec 5
|
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
|
Dec 4
|
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
|
Dec 3
|
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
|
Sep 11
|
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors
|
Aug 16
|
IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
|
Aug 10
|
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates
|
Aug 10
|
IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
|
Apr 29
|
Institutional investors are IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) biggest bettors and were rewarded after last week's US$297m market cap gain
|
Apr 28
|
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
Apr 27
|
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
|
Apr 25
|
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?
|
Apr 25
|
IDEAYA Announces Pricing of Public Offering
|
Apr 24
|
IDEAYA Announces Proposed Public Offering of Common Stock
|
Apr 24
|
IDEAYA Biosciences Touts Encouraging Data From Combo Therapy For Rare Eye Cancer Impacting Around 14,000 In US and Europe
|